The COVID-19 variant of Omicron is raging around the world, with a record number of confirmed cases in the United States, causing thousands of schools in the United States to delay returning to school or switching to distance learning. While the US Food and Drug Administration (FDA) authorized children aged 12 to 15 to be vaccinated with Pfizer Inc (PFE.US) and BioNTech (BNTX.US) to provide a third dose of COVID-19 vaccine, BioNTech shares fell 10.1 per cent last night to close at $231.85, but Pfizer Inc last night lost more than 4 per cent to close at $56.65. another vaccine stock, MRNA.US, fell 7.5 per cent to $235.05.

Vaccine and biological stocks listed in Hong Kong also generally fell today, especially CANSINOBIO-B (06185.HK), which broke 20 days, 50 days and 10 antennas (167.7-175.4 yuan), as low as 159,160 yuan, a sharp drop of 10.7 percent. INNOVENT BIO (01801.HK) has repeatedly hit bottom for two days, reaching a low of 39.7 yuan today, a low of more than a year and a half. It is now trading at 40 yuan, a further decline of 9.2%. Pioneering Pharmaceutical Industry-B (09939.HK) fell as low as 12.12 yuan, now at 12.26 yuan, down 8.1%.

Blue-chip Wuxi Biologics (02269.HK), after falling below 10 days and 20 antennas yesterday, fell further to 81.70 yuan, down 6.3%. Its parent company, 02359.HK, also fell for two days, and its share price fell 116.1 yuan today, a nine-month low, after losing 10 antennas yesterday. It is now trading at 117.7 yuan, a further decline of 6.1%.

Tengsheng Boyao-B (02137.HK) as low as 27.85 yuan, now at 28.85 yuan, a further decline of 8.8%. Shanghai Fosun Pharmaceutical (02196.HK), as low as 32.4 yuan, is now trading at 32.45 yuan, down 3.3%. Kangfang Bio-B (09926.HK) as low as 27.8 yuan, repeatedly low for more than a year, now at 28.5 yuan, down 6.3%; Corning Jerry Pharmaceutical-B (09966.HK) as low as 12.42 yuan, now at 12.64 yuan, repeatedly down 4.8%. BeiGene, Ltd. (06160.HK) fell as low as 152.1 yuan to 152.3 yuan, a further decline of 4.9 percent.

In addition, Golly Pharmaceuticals-B (01672.HK) announced the completion of Phase I clinical trials in the United States with wholly-owned independent research and development of drugs for the treatment of non-alcoholic steatohepatitis. After surging 32% yesterday, the stock further rose to 4.61 yuan this morning, a high of nearly two years, and turned around as low as 3.81 yuan. It is now trading at 4.28 yuan, down 1.6%.